NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE309.7018.95 (+6.52 %)
PREV CLOSE ( ) 290.75
OPEN PRICE ( ) 292.00
BID PRICE (QTY) 309.05 (283)
OFFER PRICE (QTY) 309.60 (714)
VOLUME 1961746
TODAY'S LOW / HIGH ( )292.00 313.35
52 WK LOW / HIGH ( )217.5 307
NSE307.9516.3 (+5.59 %)
PREV CLOSE( ) 291.65
OPEN PRICE ( ) 292.00
BID PRICE (QTY) 307.70 (925)
OFFER PRICE (QTY) 307.95 (4063)
VOLUME 39520955
TODAY'S LOW / HIGH( ) 292.00 313.40
52 WK LOW / HIGH ( )217.5 307.1
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 29-11 1978
Management Info
Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director
Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE, MCX
NEWS
20Apr Biocon informs about disclosure
Biocon has informed about a notification as follows: ‘Biocon Limited has..
18Apr Biocon, Aster DM Healthcare and Suntec
Biocon has signed an exclusive licensing and supply agreement with Biomm..
18Apr Biocon signs licensing and supply agre
Biocon has signed an exclusive licensing and supply agreement with Biomm..
18Apr Biocon shines on signing licensing and
Biocon is currently trading at Rs. 270.20, up by 7.10 points or 2.70% fr..
12Apr Biocon informs about updates
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit24028484
Gross Profit 329 29712
Operating Profit 11982949
Net Sales 562819929
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Divi's Lab (BSE)
 4004.65 (4.27%)
M.Cap (Rs. in Cr)106452.90
Abbott India (BSE)
 25870.30 (0.56%)
M.Cap (Rs. in Cr)54831.27
Astrazeneca Pharma I (BSE)
 5435.15 (2.55%)
M.Cap (Rs. in Cr)13527.38
Sanofi India (BSE)
 8256.75 (1.50%)
M.Cap (Rs. in Cr)19000.26
Alkem Laboratories (BSE)
 4930.00 (1.48%)
M.Cap (Rs. in Cr)58931.20
MORE
Shareholding Pattern
PROMOTERS 60.64%
NON-INSTITUTION 20.05%
MUTUAL FUNDS/UTI 8.57%
FI/BANKS/INSURANCE 5.02%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.